In order to counteract the inflammatory process in GBM, the use of selective COX-2 inhibitor drugs is currently evaluating being considered as an adjunct treatment, also owing to their ability to increase GBM sensitiveness to traditional chemotherapy and radiotherapy [12]. This evidence concerns the gene PTGS2 and glioblastoma.